Ergomed plc Total Voting Rights and Block Listing Return (9243Q)

TIDMERGO

RNS Number : 9243Q

Ergomed plc

01 July 2022

Total Voting Rights and Block Listing Return

Total Voting Rights

Guildford, UK - 1 July 2022 : In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 30 June 2022 consisted of 49,880,029 shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

Block Listing Six Monthly Return

 
 Name of applicant:                                       Ergomed plc 
 Name of scheme:                                          Ergomed plc Long Term Incentive Plan 
                                                         ------------------------------------------------------------- 
 Period of return:            From:                       1 January 2022              To:      30 June 2022 
                             --------------------------  --------------------------  -------  ------------------------ 
 Balance of unallotted securities under scheme(s) from 
  previous return:                                        1,908,177 
                                                         ------------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has been 
  increased since the date of the last 
  return (if any increase has been applied for):          0 
                                                         ------------------------------------------------------------- 
 Less: Number of securities issued/allotted under 
  scheme(s) during period (see LR3.5.7G):                 586,400 
                                                         ------------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period:                       1,321,777 
                                                         ------------------------------------------------------------- 
 Number and class of securities originally admitted and   1,800,000 ordinary shares of 1p each - 2 July 2018 
  the date of admission                                    1,500,000 ordinary shares of 1p each - 31 December 2019 
                                                           600,000 ordinary shares of 1p each - 7 July 2021 
                                                         ------------------------------------------------------------- 
 Total number of securities in issue at the end of the    49,880,029 ordinary shares of 1p each 
  period 
                                                         ------------------------------------------------------------- 
 
 
 
 Name of contact:                Fiona Mundy - Director of Group Reporting 
 Telephone number of contact:    [phone] 
                                ------------------------------------------ 
 

ENDS

Enquiries :

Ergomed plc Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)

Peel Hunt LLP Tel: [phone]

James Steel / Dr Christopher Golden

   Consilium Strategic Communications                                   Tel: [phone] 

Chris Gardner / Matthew Neal [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBBLLXLQLFBBL

(END) Dow Jones Newswires

July 01, 2022 02:00 ET (06:00 GMT)